RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Waldenström Macroglobulinaemia: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
A Cold and Viscous Clue: Waldenström Macroglobulinemia Presenting With Secondary Cold Agglutinin Syndrome and Hyperviscosity Syndrome
Fukai L. Chuang et al., Cureus (18 October 2026)
https://doi.org/10.7759/cureus.118118
- 2.
Crystalline κ-light-chain proximal tubulopathy in Waldenström macroglobulinemia with an IgA nephropathy pattern: a case report and systematic review
Jun Zhang et al., Frontiers in Immunology (15 October 2026)
https://doi.org/10.3389/fimmu.2026.1942324
- 3.
Severe Aplastic Anemia Concurrent with Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia.
Okuda Takehiro et al., Internal medicine (Tokyo, Japan) (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/41813169/
- 4.
The Challenges Associated with the Diagnosis and Treatment for Aplastic Anemia Concurrent with Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia.
Sekiguchi Naohiro, Internal medicine (Tokyo, Japan) (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/41813174/
- 5.
Does Waldenstrom's macroglobulinemia cause bone pain?
Tripdatabase, Zenodo (CERN European Organization for Nuclear Research) (10 October 2026)
https://doi.org/10.5281/zenodo.23279805
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
NCT07249905 · Recruiting · Phase 1 / Phase 2 · ModeX Therapeutics, An OPKO Health Company
Ages 18 and over
https://clinicaltrials.gov/study/NCT07249905
- 2.
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716 · Recruiting · Phase 1 / Phase 2 · BeOne Medicines
Ages 18 and over
https://clinicaltrials.gov/study/NCT05006716
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Waldenström Macroglobulinaemia
Waldenström macroglobulinaemia is a rare slow-growing cancer of white blood cells in the bone marrow. The abnormal cells make too much of an antibody called IgM, which can thicken the blood and cause tiredness, anaemia, bleeding, nerve problems and swollen glands. Some people need no treatment at first. When needed, treatment includes immunotherapy, chemotherapy and targeted medicines.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common Questions
What is Waldenström Macroglobulinaemia?
Waldenström macroglobulinaemia is a rare slow-growing cancer of white blood cells in the bone marrow. The abnormal cells make too much of an antibody called IgM, which can thicken the blood and cause tiredness, anaemia, bleeding, nerve problems and swollen glands. Some people need no treatment at first. When needed, treatment includes immunotherapy, chemotherapy and targeted medicines.
How many clinical trials are available for Waldenström Macroglobulinaemia?
RareWays currently indexes 330 clinical trials for Waldenström Macroglobulinaemia, of which 31 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Waldenström Macroglobulinaemia come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Waldenström Macroglobulinaemia.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.